144 related articles for article (PubMed ID: 12385411)
1. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.
Omar A; Kempf C
Transfusion; 2002 Aug; 42(8):1005-10. PubMed ID: 12385411
[TBL] [Abstract][Full Text] [Related]
2. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
3. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
4. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
5. Choice of parvovirus model for validation studies influences the interpretation of the effectiveness of a virus filtration step.
Nowak T; Popp B; Roth NJ
Biologicals; 2019 Jul; 60():85-92. PubMed ID: 31105022
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus].
Oh DJ; Lee YL; Kang JW; Kwon SY; Cho NS; Kim IS
Korean J Lab Med; 2010 Feb; 30(1):45-50. PubMed ID: 20197722
[TBL] [Abstract][Full Text] [Related]
7. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.
Parkkinen J; Rahola A; von Bonsdorff L; Tölö H; Törmä E
Vox Sang; 2006 Feb; 90(2):97-104. PubMed ID: 16430667
[TBL] [Abstract][Full Text] [Related]
8. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
9. Extent of hepatitis E virus elimination is affected by stabilizers present in plasma products and pore size of nanofilters.
Yunoki M; Yamamoto S; Tanaka H; Nishigaki H; Tanaka Y; Nishida A; Adan-Kubo J; Tsujikawa M; Hattori S; Urayama T; Yoshikawa M; Yamamoto I; Hagiwara K; Ikuta K
Vox Sang; 2008 Aug; 95(2):94-100. PubMed ID: 18714441
[TBL] [Abstract][Full Text] [Related]
10. Virus inactivation of plasma-derived proteins by pasteurization in the presence of guanidine hydrochloride.
Schlegel A; Immelmann A; Kempf C
Transfusion; 2001 Mar; 41(3):382-9. PubMed ID: 11274595
[TBL] [Abstract][Full Text] [Related]
11. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.
Roth NJ; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gröner A; Gustafson M; Jorquera JI; Kreil TR; Misztela D; Moretti E; Moscardini M; Poelsler G; More J; Roberts P; Wieser A; Gajardo R
Transfusion; 2020 Nov; 60(11):2661-2674. PubMed ID: 32815181
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
13. Removal of parvovirus B19 from hemoglobin solution by nanofiltration.
Abe H; Sugawara H; Hirayama J; Ihara H; Kato T; Ikeda H; Ikebuchi K
Artif Cells Blood Substit Immobil Biotechnol; 2000 Sep; 28(5):375-83. PubMed ID: 11009110
[TBL] [Abstract][Full Text] [Related]
14. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step.
Koenderman AH; ter Hart HG; Prins-de Nijs IM; Bloem J; Stoffers S; Kempers A; Derksen GJ; Al B; Dekker L; Over J
Biologicals; 2012 Nov; 40(6):473-81. PubMed ID: 22901944
[TBL] [Abstract][Full Text] [Related]
15. Detection of rodent parvoviruses by use of fluorogenic nuclease polymerase chain reaction assays.
Redig AJ; Besselsen DG
Comp Med; 2001 Aug; 51(4):326-31. PubMed ID: 11924790
[TBL] [Abstract][Full Text] [Related]
16. Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data.
Gröner A
Biotechnol Prog; 2024; 40(1):e3398. PubMed ID: 37985214
[TBL] [Abstract][Full Text] [Related]
17. Increasing the capacity of parvovirus-retentive membranes: performance of the Viresolve Prefilter.
Bolton GR; Spector S; Lacasse D
Biotechnol Appl Biochem; 2006 Jan; 43(Pt 1):55-63. PubMed ID: 16207176
[TBL] [Abstract][Full Text] [Related]
18. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
19. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa.
Ellgaard TW; Bindslev L; Kamstrup S
Protein Expr Purif; 2017 Jan; 129():94-100. PubMed ID: 27620499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
